Our comprehensive preclinical evaluation across diverse HCC models establishes that NKG2D-directed CAR-Ms achieve robust antitumor efficacy, characterized by profound tumor burden reduction, metastasis suppression, and survival prolongation. This evidence concerns the gene KLRK1 and neoplasm.